News Quantified

SGMT – sagimet biosciences inc. (US:NASDAQ)

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

5/6

08:13 am

sgmt

Medium

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer [Yahoo! Finance]

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Sagimet Biosciences Inc. (NASDAQ: SGMT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $32.00 price target on the stock.

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity [Seeking Alpha]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}